FGI 103

an antiviral; structure in first source
Also Known As:
FGI-103; FGI103
Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results


1. De Clercq, Erik: 1 article (11/2013)
2. Aman, M Javad: 1 article (05/2010)
3. Goldblatt, Michael: 1 article (05/2010)
4. Kinch, Michael S: 1 article (05/2010)
5. Enterlein, Sven: 1 article (05/2010)
6. Yunus, Abdul S: 1 article (05/2010)
7. Ruthel, Gordon: 1 article (05/2010)
8. Smith, Mark: 1 article (05/2010)
9. Warren, Travis K: 1 article (05/2010)
10. Bavari, Sina: 1 article (05/2010)

Related Diseases

1. Infection
05/01/2010 - "In vivo administration of FGI-103 as a single intraperitoneal dose of 10 mg/kg delivered 24 h after infection is sufficient to completely protect mice against a lethal challenge with a mouse-adapted strain of either ZEBOV or MARV-Ravn. "
05/01/2010 - "In a murine model of ZEBOV infection, delivery of FGI-103 reduces viremia and the viral burden in kidney, liver, and spleen tissues and is associated with subdued and delayed proinflammatory cytokine responses and tissue pathology. "
11/01/2013 - "Prominent in the current stage of antiviral drug development are: (i) for human immunodeficiency virus (HIV), the use of fixed-dose combinations (FDCs), the most recent example being Stribild(TM); (ii) for hepatitis C virus (HCV), the pleiade of direct-acting antivirals (DAAs) that should be formulated in the most appropriate combinations so as to obtain a cure of the infection; (iii)-(v) new strategies (i.e., AIC316, AIC246, and FV-100) for the treatment of herpesvirus infections: herpes simplex virus (HSV), cytomegalovirus (CMV), and varicella-zoster virus (VZV), respectively; (vi) the role of a new tenofovir prodrug, tenofovir alafenamide (TAF) (GS-7340) for the treatment of HIV infections; (vii) the potential use of poxvirus inhibitors (CMX001 and ST-246); (viii) the usefulness of new influenza virus inhibitors (peramivir and laninamivir octanoate); (ix) the position of the hepatitis B virus (HBV) inhibitors [lamivudine, adefovir dipivoxil, entecavir, telbivudine, and tenofovir disoproxil fumarate (TDF)]; and (x) the potential of new compounds such as FGI-103, FGI-104, FGI-106, dUY11, and LJ-001 for the treatment of filoviruses (i.e., Ebola). "
2. HIV Infections (HIV Infection)
3. Viremia
4. Herpesviridae Infections (Herpesvirus Infection)

Related Drugs and Biologics

1. Lamivudine (3TC)
2. Antiviral Agents (Antivirals)
3. R 125489
4. cidofovir hexadecyloxypropyl ester
5. telbivudine
6. tenofovir disoproxil (Viread)
7. peramivir
8. entecavir
9. adefovir dipivoxil (Hepsera)
10. tenofovir